Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

China Pharma Holdings (CPHI) Research & Development (2016 - 2025)

China Pharma Holdings filings provide 13 years of Research & Development readings, the most recent being $190041.0 for Q4 2025.

  • On a quarterly basis, Research & Development rose 34642.41% to $190041.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $280901.0, a 1.07% decrease, with the full-year FY2025 number at $280901.0, down 1.07% from a year prior.
  • Research & Development hit $190041.0 in Q4 2025 for China Pharma Holdings, up from $40321.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $190086.0 in Q1 2021 to a low of $547.0 in Q4 2024.
  • Median Research & Development over the past 5 years was $43047.0 (2023), compared with a mean of $65487.2.
  • Biggest five-year swings in Research & Development: plummeted 99.63% in 2024 and later surged 34642.41% in 2025.
  • China Pharma Holdings' Research & Development stood at $54048.0 in 2021, then plummeted by 48.2% to $27999.0 in 2022, then surged by 426.99% to $147552.0 in 2023, then plummeted by 99.63% to $547.0 in 2024, then surged by 34642.41% to $190041.0 in 2025.
  • The last three reported values for Research & Development were $190041.0 (Q4 2025), $40321.0 (Q3 2025), and $20952.0 (Q2 2025) per Business Quant data.